This brief review focuses on experimental studies linking the proinflammatory cytokine tumor necrosis factor-␣ to accelerated vein graft failure in the broader historical context of vein graft research. From some perspectives, the field appears ripe for transfer of cytokine knowledge and therapeutic approaches that have evolved in other systems to vascular surgery problems. However, the complexity of vein graft disease suggests that more robust research approaches, such as broadening of the scope beyond focus on single mediators and neointimal hyperplasia, will be necessary to reach translatable strategies to prolong human vein graft durability. ( J Vasc Surg 2007;45:92A-98A.)
Surgical bypass with autologous vein remains an evidence-based treatment of choice for selected patients with infrainguinal lower extremity or coronary occlusive disease. However, contemporary data show that almost 40% of lower extremity vein bypass grafts develop occlusive lesions or fail within a year, 1 and almost half of cardiac bypass patients will lose (Ն75% stenosis) a vein graft within a year. 2 Because many technical avenues for improved patency have been exhausted, the future of enhancing the durability of these reconstructions lies in a better knowledge of and interventions based on the biology of the vein graft wall.
This article briefly reviews vein graft failure research to date and then focuses on the proinflammatory cytokine tumor necrosis factor-␣ (TNF-␣) and the early vein graft. Finally, the current status of the field is outlined in the context of cytokine-based research, and challenges and opportunities for the future are discussed. Certainly, a multitude of biochemicals, including growth factors and cell cycle regulators, have been linked to mechanisms of vein graft failure, and the following is by no means comprehensive.
EVOLUTION OF CURRENT VEIN GRAFT CONCEPTS
Vein grafts undergo a defined sequence of anatomic adaptations after placement, although not all favor longterm patency. The principal cause of failure is traditionally cited as the development of neointimal hyperplasia that leads to an obliterative stenosis. [3] [4] [5] [6] [7] Early work in the vein graft research field focused on mechanical factors. [3] [4] [5] 8 Like arteries, vein graft wall structure adapts to the hemody-namic environment, 9, 10 although there may be some subtle wall differences. 5 Intimal hyperplasia has been noted to occur at vein graft areas of low flow, 3 probably areas of low wall shear stress. 4, 8 Conversely, high flow appears to have protective effects 6, 11 in association with decreased wall inflammation. 12 The early 1990s also brought a recognition of the importance of circumferential wall tension on the adapting vein graft. 5, 13 The 1990s saw increased recognition in vascular biology of the interplay between the inflammatory and cardiovascular systems. The arterial wall response to injury was associated with early inflammatory events, including monocyte and T-cell adhesion to vascular endothelial cells. [14] [15] [16] Platelet activation and mural thrombus formation were also implicated in this cascade, as well as cytokine and growth factor elaboration, all leading to subsequent vascular remodeling 17 through cellular migration, proliferation, and matrix deposition. [14] [15] [16] 18, 19 In the mid-1990s, these paradigms began to transfer to the vein graft arena. 20 Works specifically examined the role of inflammatory mediators in vein graft failure. 10, [21] [22] [23] [24] For instance, the macrophage was identified as a pivotal cellular mediator of vein graft neointimal hyperplasia, with macrophage depletion suppressing this process. 22 Despite incremental progress over these decades, specific cause-and-effect links between hemodynamic factors, inflammatory biochemical mediators, cellular effectors, and vein wall adaptations remain lacking. Thus, not surprisingly, few therapeutic agents to improve vein graft durability have been identified. Antiplatelet and anticoagulant approaches show only a modest benefit under specific circumstances. 25, 26 Recent trials testing edifoligide (an oligonucleotide decoy that binds to and inhibits E2F transcription factors) failed to yield substantial clinical benefit. 1,2 almost a decade ago, 10, 23 although the initiating factors for their expression and the biologic implications of these inflammatory mediators in vein wall adaptations remained largely unknown. Expanding knowledge in cytokine-driven inflammatory pathways in other organ systems has led to effective methods for treating pathologies such as rheumatoid arthritis and inflammatory bowel disease, [27] [28] [29] [30] [31] [32] [33] [34] [35] and several anti-inflammatory cytokine-based pharmacologic compounds have emerged. [36] [37] [38] Although anti-inflammatory cytokine therapies have received recent attention as a means to abrogate primary arterial occlusive disease, 39 cytokine manipulation strategies remain relatively unexplored with regards to vein graft failure.
TNF-␣ is a pleiotropic proinflammatory cytokine. 40, 41 Its expression is controlled at the level of both gene transcription and translation, and it can be synthesized by several cell lines relevant to vascular biology, including macrophages, T cells, endothelial cells, fibroblasts, and smooth muscle cells. 42, 43 This potent proinflammatory cytokine is initially synthesized and processed to a transmembrane form. 44 TNF-␣-converting enzyme (TACE), a member of the matrix metalloproteinase superfamily, releases TNF-␣ from the cell surface, 45, 46 and as a homotrimer, the soluble TNF-␣ elicits responses in distal target cells. 43 Since its description over three decades ago, several related ligands have been described and are grouped in a TNF superfamily of genes. 47 The tissue response to TNF-␣ is mediated through two distinct receptors, p55 (type 1 TNF receptor) and p75 (type 2 TNF receptor). 40, 48 These receptors belong to a large TNF receptor superfamily that also includes nerve growth factor receptor, CD95, and Apo2. 47, 49, 50 Most cell types coexpress both TNF receptors, although expression of the two receptors appears to be differentially regulated and shows tissue-specific prevalence. Of more importance is that the two receptors differ markedly in their intracellular structure and signaling pathways. 40, 43 Most of the proinflammatory responses classically attributed to TNF-␣ appear to be mediated by p55 signaling. Studies have shown that administration of TNF-␣ muteins with specificity for the p55 receptor are proinflammatory and shock inducing, whereas p75 muteins lack any proinflammatory properties. 51, 52 The theory for a pivotal role for TNF-␣ in vein graft neointima formation and the related pathologic process of atherogenesis is founded on in vitro cell culture studies, pathologic observations, and a limited number of in vivo studies. In cell culture, TNF-␣ augments expression of intercellular adhesion molecules in human vascular endothelial cells 53 and vascular smooth muscle cells, 54 thus increasing the possibility of interactions between mononuclear cells, endothelial cells, and smooth muscle cells in neointimal lesions and atherosclerotic plaques. In addition, TNF-␣ induces prostanoid synthesis, corticosteroids, and other cytokines, 41 and stimulates smooth muscle cell migration 55 and proliferation after vascular injury. 42 Through receptors, TNF-␣ signaling activates caspases, leading to apoptosis, mitogen-activated protein kinases and nuclear factor-B, 40 which are intracellular mediators linked to numerous fundamental vascular processes.
Few studies have extended these in vitro cell culture and pathologic studies into the more complex in vivo vascular setting. Pathologically, TNF-␣ co-localizes to areas of occlusive lesions in human arteries 56 and arterialized vein grafts. 23 In a rabbit heterotopic cardiac transplantation model, in vivo blockade of TNF-␣ by way of TNF soluble receptor suppressed the acute development of neointima formation by selectively reducing the vascular inflammatory reaction and accumulation of fibronectin. 57 Nonetheless, the mechanisms of transplant atherosclerosis may be quite different from those of vein graft neointimal hyperplasia. Another set of in vivo experiments demonstrated that exogenous TNF-␣ causes coronary arteriosclerosis-like cellular changes in a porcine model. 58
RECENT RESEARCH
For the last decade, our group has probed the role of cytokines in vascular biology. We were initially interested in the role of TNF-␣ in low shear stress-induced arterial intimal hyperplasia. Using murine models and molecular approaches, we documented induction of TNF-␣ by acute lowering of arterial wall shear stress. 59 We have also probed the role of cytokine signaling in the arterial wall response to high shear stress. TNF-␣ was shown to co-localize to areas of active positive remodeling in response to increased wall shear stress. 60 Working with collaborators, we completed experiments that used a novel murine model of arteriogenesis, a clinically relevant form of outward arterial remodeling in response to increased wall shear stress. The results showed that TNF-␣ positively modulated arteriogenesis, probably signaling through the p55 receptor. 61 Recent experiments demonstrate that this process is blocked with the administration of TNF-␣ inhibitors. 62 From these findings linking vascular wall adaptations with changes in hemodynamic environment through proinflammatory and anti-inflammatory cytokine signaling, we hypothesized similar mechanisms in the vein graft. The vein graft is essentially an extreme example of acute hemodynamic change, coupled with a local injury response, leading to morphologic adaptations within the vascular wall. We developed and validated a rabbit bilateral jugular vein into carotid artery vein graft model with clinically relevant differential hemodynamic environments. 6, [63] [64] [65] In this model, unilateral reduction in carotid artery (and thus vein graft) flow is accomplished by the placement of 8-0 silk suture ligatures to completely occlude the internal carotid and three of the four primary branches of the external carotid artery. Distal branch ligation results in an immediate 90% flow reduction (P Ͻ .001) in the vein graft on the ligated side and 36% flow augmentation (P ϭ .01) in the contralateral vein graft. The vein grafts develop physiologically relevant levels of wall shear and neointimal hyperplasia volume that is inversely proportional to wall shear.
To initiate studies into molecular mediators of these vein graft adaptations, quantitative real-time two-step poly-merase chain reaction (RT-PCR) was performed for TNF-␣, IL-1␤, and IL-10 on the paired high and low wall shear vein grafts in this rabbit model longitudinally. The results revealed several shear and time-dependent cytokine expression signatures (Fig 1) . 66, 67 TNF-␣ induction was maximal at day 1 and gradually decreased over time, but was persistently elevated even 4 weeks later (P Ͻ .001). Low shear (associated with increased neointimal hyperplasia) resulted in significantly higher TNF-␣ messenger RNA (mRNA) expression (P ϭ .03). TNF-␣ was induced 198-fold and 110-fold in low and high shear vein grafts, respectively, by the first day after arterialization. This elevation gradually decreased over time but was persistently elevated from baseline even 4 weeks later (P Ͻ .001). Over the course of the study, low shear resulted in significantly higher TNF-␣ mRNA (P Ͻ .003) vein graft wall expression.
Although the general expression pattern of IL-1␤ expression mirrored that of TNF-␣, several notable differences exist. At day 1, IL-1␤ was induced a striking 1188fold and 366-fold in low and high shear vein grafts, respectively, but the return toward baseline was more rapid. Flow impacted IL-1␤ expression overall (P Ͻ .001), although the differential was greatest at the 1-day (P ϭ .002) and 3-day (P Ͻ .0001) time points. Consistent with the theory that proinflammatory cytokine mechanisms drive downstream vein graft adaptations, these early quantitative TNF-␣ and IL-1␤ mRNA level changes were temporally distinct from the time course of later morphologic and cellular changes in the vein graft wall. High proinflammatory cytokine levels (as in the low-flow setting) correlated positively with greater intimal hyperplasia. Immunohistochemistry analysis shows that TNF-␣ and IL-1␤ protein localize to the vein intima in the first 3 days after graft placement.
Finally, vein graft arterialization more slowly and modestly induced IL-10 mRNA expression. Overall, this occurred independent of shear (P ϭ .152), although there was a statistically significant higher expression for high shear grafts at the 14-day time point (P Ͻ .001). IL-10 is an immunosuppressive and anti-inflammatory cytokine produced by T cells, B cells, natural killer cells, and monocyte/ macrophage cell lines. 12, 68 It has been shown to suppress the production of numerous inflammatory cytokines, including TNF-␣. 41 Conversely, TNF-␣ is a principal inducer of IL-10 biosynthesis. 69 This acts in a negative feedback loop to suppress TNF-␣ production and processing. IL-10 is believed to exert its anti-inflammatory effects on the vascular system through inhibition of leukocyteendothelial cell interactions and inhibition of proinflammatory cytokine and chemokine production. 12, 68 In support of the hypothesis that the anti-inflammatory cytokine IL-10 downregulates vein graft neointimal hyperplasia, researchers have demonstrated an effect of IL-10 on vascular smooth muscle cell proliferation. Physiologic doses of IL-10 inhibited TNF-␣ and basic fibroblast growth factorstimulated DNA synthesis and cell proliferation, 70 suggesting that endogenous IL-10 not only suppresses proinflammatory cytokine expression, but also may antagonize pathologic vascular remodeling induced by cytokines such as TNF-␣. 70 These results 66, 67 in the context of the medical literature 10,23,71-75 led our group to formulate the general hypothesis outlined in Fig 2. As an initial step to test this hypothesis, we used a pharmacologic approach to abrogate TNF-␣ signaling in the early vein graft of our validated rabbit model. 66 Animals received pegylated soluble TNF-␣ type I receptor (PEG sTNF-RI; Amgen, Thousand Oaks, Calif) or vehicle with either short-term or long-term dosing. PEG sTNF-RI is a 20-kd molecule containing a homodimer of human p55 covalently linked to a polyethylene glycerol backbone. 76 Molecular modification of these pegylated receptors through deletion of 1.4 intracellular domains reduces immunogenicity but has no impact on ligand binding. 77 Because of a conserved sequence homology, the compound has been demonstrated to abrogate the adaptive immune response across a range of species, including rabbits. 76, 78 After 14 to 28 days, grafts were analyzed. PEG sTNF-R1 was found in high concentrations in the serum TNF␣, Tumor necrosis factor-␣; IL-1, interleukin. Data are combined from two prior J Vasc Surg reports. 66, 67 and localized to neointimal hyperplasia microscopically. Both high-flow and low-flow vein grafts from treated animals demonstrated similar volumes of neointimal hyperplasia compared with controls. PEG sTNF-R1 had minimal impact on vascular wall cell turnover, as reflected by terminal deoxynucleotide transferase-mediated deoxy uridine triphosphate nick-end labeling (TUNEL) and anti-Ki-67 assays. 66 Thus, although placement of a vein into the arterial circulation acutely upregulates TNF-␣ 23,66,75 (whose expression level correlates with the degree of subsequent neointimal hyperplasia), pharmacologic interruption of this signaling pathway has no significant impact on neointimal hyperplasia or smooth muscle cell proliferation and apoptosis. 66 These data suggest that early vein graft adaptations can proceed by TNF-␣ independent mechanisms. Recent work by other investigators, however, supports a differing conclusion. In a study that used p55 receptor knockout animals, functional TNF-␣ inhibition was shown to attenuate vein graft neointimal hyperplasia. 71 Further investigation is required to elucidate these apparently contrasting observations.
Interesting comparisons can be drawn with observed challenges in application of anti-inflammatory approaches in other pathologies. Early anti-TNF-␣ clinical trials in acute inflammatory processes, such as sepsis, have had disappointing results [79] [80] [81] [82] and may be attributed to an over-simplistic view of these disease processes and TNF-␣mediated cytotoxicity. 41 A similar situation arose in the setting of anti-TNF-␣ trials for heart failure. 83 These experiences may have lessons for work with the vein graft. We have recently completed microarray analyses of vein graft wall in both mice and rabbits (both high flow and low flow). 84 The results reveal a large number of gene perturbations across multiple families of mediators. These results show that the overwhelming determinant of the wall's transcriptome is the temporal relationship with the operative graft placement; that is, the trauma of the operation itself, rather than the details (eg, neointimal volume) of the wall adaption. Thus, it may be naive to believe that abrogation of a single mediator would have substantial lasting impact on the final morphology of the wall. Perhaps strategies that block central signaling molecules that control numerous genes for various cytokines and adhesion molecules will be effective (eg, nuclear factor-B), 85 although targets such as TNF-␣ seem to meet this criteria.
FUTURE CONSIDERATIONS AND DIRECTIONS
To date, several lessons have become apparent, and some considerations for future progress are summarized:
• Single-agent vs multiagent strategies. Narrowly focused molecular targets hold the appeal of limited unwanted side effects. However, in view of the large number of mediators implicated in the vein graft wall adaptation, perturbation of several pathways may be necessary to consistently achieve substantial and durable effect. For example, multimodality approaches stand as a mainstay of antineoplastic therapies. The multitude of processes involved in vein graft failure support the use of such strategies, yet the rationale and safety of each component must be confirmed, and substantial investigative work will be required to define the composition of this synergistic cocktail. Emerging endovascular approaches bring into question the relevance of vein graft research. However, contemporary evidence-based guidelines confirm that a substantial portion of our aging population will require vein conduits for arterial revascularization. In addition, basic biologic mechanisms delineated in the vein graft field hold a strong likelihood of relevance for other vascular responses to injury.
CONCLUSION
Understanding the cytokine-mediated molecular mechanisms of vein graft arterialization may suggest clinical interventions that will alter the conduit's natural history. The field appears especially ripe for transfer of knowledge and therapeutic approaches that have evolved in the arterial system as well as inflammatory mediated processes such as inflammatory bowel disease and arthritis. However, more robust research approaches such as broadening of the scope beyond focus on single mediators and neointimal hyperplasia will be necessary to reach translatable strategies to prolong human vein graft durability. I gratefully acknowledge the editorial assistance of Dr Scott A. Berceli and Dr Zhihua Jiang.
